Tirzepatide Suppliers & Bulk Manufacturers
Available Forms: injection (prefilled syringe)
Available Strengths: 2.5 mg / 0.5 mL, 5 mg / 0.5 mL
Reference Brands: Mounjaro (USA/EU), Zepbound (USA)
Category:
Diabetes
Tirzepatide is a novel once-weekly injectable peptide medication that acts as a dual GIP (glucose-dependent insulinotropic polypeptide) receptor agonist and GLP-1 (glucagon-like peptide-1) receptor agonist. It is used for the treatment of type 2 diabetes mellitus and, under certain brand names, for chronic weight management.
Tirzepatide is available in injection (prefilled syringe)
and strengths such as 2.5 mg / 0.5 mL, 5 mg / 0.5 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tirzepatide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tirzepatide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Tirzepatide is a novel, first-in-class dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, approved by the US FDA for the treatment of Type 2 diabetes mellitus (T2DM). By simultaneously activating both incretin pathways, tirzepatide enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite. This dual mechanism contributes to significant improvements in glycemic control and weight reduction, providing therapeutic benefits comparable to GLP-1 receptor agonists like semaglutide.
In addition to its use in T2DM, tirzepatide has shown substantial efficacy in weight management, making it a potential therapeutic option for obesity. It is administered as a subcutaneous injection once weekly, with doses titrated based on clinical response and tolerability. Clinical trials have demonstrated that tirzepatide is effective in reducing HbA1c, lowering fasting blood glucose, and promoting sustained weight loss, while maintaining a favorable safety profile.
Tirzepatide represents a significant advancement in metabolic therapy, offering dual benefits for glycemic control and weight management, and is an important treatment option for patients with T2DM, particularly those with obesity or cardiovascular risk factors.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing